NCT01955668 - AZD6738 First Time in Patient Multiple Ascending Dose Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),Prolymphocytic Leukaemia (PLL)B Cell Lymphomas

Interventions

DRUG

Administration of AZD6738

An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially

Trial Locations (1)

Unknown

Research Site, La Jolla